人高迁移率族蛋白B1，高迁移率族蛋白B1 A box和B box的原核表达、 纯化及高迁移率族蛋白B1多克隆抗血清的制备

目的:获取重组人高迁移率族蛋白B1(HMGB1),HMGB1Abox和Bbox的纯化蛋白,制备HMGB1的多克隆抗血清。方法:采用PCR方法扩增人HMGB1,HMGB1的Abox和Bbox目的基因片段,构建原核表达载体,进行原核表达与蛋白纯化,然后用HMGB1免疫新西兰大白兔,制备多克隆抗血清。采用ELISA检测抗血清效价,用免疫组化检测HMGB1在小鼠肝损伤组织中的表达。结果:成功构建了人HMGB1,HMGB1的Abox和Bbox原核表达载体pET28-HMGB1、pET28-Abox、pET28-Bbox,在E.coli BL21中表达,镍亲和层析柱提纯,获取纯净目的蛋白。HMGB1免疫新西兰大白兔后,抗血清效价为1:2,000,000,具有高度特异性。免疫组化显示小鼠坏死肝组织HMGB1表达增加。结论:本研究获得了人HMGB1以及HMGB1的Abox和Bbox的纯化蛋白,制备了人HMGB1的多克隆抗血清,为HMGB1的结构、组织表达谱及其功能的研究奠定了基础。     

神经纤毛蛋白-1的原核表达及兔抗小鼠神经纤毛蛋白-1抗体免疫学活性的研究

目的:在原核系统中分段表达神经纤毛蛋白-1(Nrp1);将纯化的蛋白免疫家兔后获得特异的抗体,并将其应用于检测组织和细胞中Nrp1分子的表达。方法:提取BALB/c胎鼠脑组织总RNA,通过RT-PCR分段扩增获得Nrp1基因片段,将PCR产物插入表达载体pET28a( ),获得含5个Nrp1基因片段的重组质粒,在大肠杆菌BL21(DE3)中诱导蛋白表达并纯化;将纯化的重组蛋白免疫新西兰大白兔获得针对目的蛋白的特异性多克隆抗体;利用Nrp1特异性多抗检测胎鼠脑组织和HeLa细胞中Nrp1的表达。结果:在原核系统中分段表达了Nrp1蛋白,通过Ni-NTA纯化了Nrp1蛋白片段;纯化的Nrp1蛋白免疫新西兰大白兔获得了具有免疫活性的多抗;兔抗小鼠Nrp1特异性多抗可用于检测组织、真核细胞中Nrp1的表达。结论:应用原核系统成功地表达了Nrp1蛋白,兔抗小鼠Nrp1特异性多抗可用于免疫学检测Nrp1分子的表达。     

DNA损伤检查点蛋白调节子1片段的表达纯化及抗体制备

目的：原核表达、纯化DNA损伤检查点蛋白调节子1（MDC1）片段,并制备其多克隆抗体。方法：设计特异引物,通过RT-PCR扩增编码MDC1 N端194个氨基酸残基的基因片段,测序正确后插入含GST基因的原核表达载体pGEX-KG中,以IPTG诱导表达,并经谷胱甘肽琼脂糖珠纯化融合蛋白;用纯化的蛋白免疫小鼠制备多克隆抗体,用ELISA测定抗体的效价,Western印迹鉴定抗体的特异性。结果：原核表达并纯化了MDC1 N端片段,并获得了抗MDC1的多克隆抗体,抗体效价达到1∶12800,Western印迹显示该抗血清能特异识别原核及真核细胞表达的MDC1。结论：MDC1 N端片段能够诱导小鼠产生具有较高效价和特异性的多克隆抗体,为进一步研究MDC1在Fhit特异信号通路中的作用奠定了基础。     

人PD1胞外须基因的克隆、蛋白表达及抗体制备

目的：研究人PD1的生物学活性,制备人PD1胞外段区域及其特异性抗体。方法：用PCR方法扩增编码人PD1胞外段的基因序列（hPD1ecr）,将其克隆到原核表达载体pET28a（＋）中,并转化至大肠杆菌BL21（DE3）中诱导表达,表达蛋白用SDS-PAGE和Western blot鉴定。纯化目的蛋白免疫日本大耳白兔,制备多克隆抗体。通过酶联免疫吸附实验（ELISA）,流式细胞术检测抗体滴度及其特异性。结果：原核表达载体pET28a（＋）-PD1ecr成功构建,并可在大肠杆菌BL21（DE3）中诱导表达,得到的PD1胞外区蛋白经SDS-PAGE和Western blot鉴定正确。用纯化蛋白免疫日本大耳白兔,制备的多克隆抗体具有较强免疫特异性。结论：得到纯化的人PD1胞外蛋白,制备的多克隆抗体能够检测自然状态下人PD1蛋白,为进一步研究PD1功能奠定了实验基础。     

人HMGB1 B Box的表达及其生物活性

经RTPCR从人新鲜扁桃体组织中扩增人高迁移率族蛋白B1(HMGB1)中的Bbox(88～162残基)的cDNA,构建于载体pUC19,经测序后与GenBank中报道的已知序列完全一致,再构建于原核表达载体pQE80LDHFR中,表达并鉴定目的蛋白.经Ni2+亲和层析柱、多粘菌素B层析柱纯化获得高纯度的DHFRHMGB1Bbox蛋白,然后将此重组HMGB1Bbox加入到人外周血单核细胞(PBMCs)中,37℃,5%CO2下,刺激PBMCs6h,用ELISA检测PBMCs释放TNFα、IL6的量,经检测后证明纯化后的重组HMGB1Bbox能显著地刺激PBMCs释放致炎因子TNFα、IL6.HMGB1Bbox的表达及其生物活性的初步研究,为进一步研究HMGB1Bbox的作用机制以及新型抗炎制剂的研发奠定基础.     

人源核受体hLRH-1 的表达纯化及多克隆抗体制备

目的：制备抗人源核受体hLRH-1 的多克隆抗体,为进一步研究其功能奠定基础。方法：构建含有hLRH-1基因全长克隆的 原核表达载体pET507a-hLRH-1 并用IPTG 诱导其在Rosseta2 菌株中表达重组蛋白His-hLRH-1,经亲和层析纯化后按常规方法 免疫新西兰兔制备多克隆抗体,并用Western Blot 对其特异性进行鉴定。结果：原核表达载体pET507a-hLRH-1经测序证实构建 成功,将其转化大肠杆菌Rosseta2菌株后成功诱导表达重组蛋白His-hLRH-1,经纯化免疫新西兰兔后得到抗hLRH-1 多克隆抗 体,Western blot 证实抗体具有高度特异性。结论：成功表达His-hLRH-1 重组蛋白并制备出多克隆抗体,为进一步用于hLRH-1 的 免疫学检测及其功能研究奠定了基础。     

跨膜逆向转运蛋白NHXFS1多克隆抗体的制备及应用

NHXFS1基因是通过DNA家族改组（DNA family shuffling）技术,以拟南芥、水稻和菊花的液泡膜Na＋/H＋逆向转运蛋白基因（NHX1）为亲本获得的活性显著增强的新基因。为制备该蛋白的多克隆抗体,对该蛋白进行跨膜结构分析,选取跨膜蛋白的C末端为靶标,并将其克隆到原核表达载体pET32a中,成功构建了原核融合蛋白pET32a-NHXFS1-抗原表达载体,转化大肠杆菌BL21（DE3）并诱导表达。通过镍柱亲和层析纯化该融合表达蛋白,获得了纯度约为80%的纯化蛋白,用于免疫新西兰大白兔制备多克隆抗体。ELISA实验表明,该抗体的效价达到1：128 000,提取表达NHXFS1蛋白的酵母液泡经该多克隆抗体Western blot检测,证明该抗体具有较好的NHXFS1蛋白特异性。NHXFS1多克隆抗体的制备为进一步认识NHXFS1新蛋白结构与功能以及植物耐盐分子生物学的研究奠定了基础。     

人类博卡病毒(HBoV)非结构蛋白NS1基因的克隆、原核表达及多克隆抗体的制备

目的:克隆、表达、纯化人类博卡病毒(HBoV)非结构蛋白NS1,制备抗NS1多克隆抗体。方法:利用PCR扩增HBoV非结构蛋白NS1基因,将其克隆至pMAL-c2X表达载体上,重组质粒转化大肠杆菌DH10B,IPTG诱导表达。表达的融合蛋白经Amylose Resin亲和层析柱纯化后,免疫新西兰大白兔制备多克隆抗体。用间接ELISA法检测抗体效价。结果:原核表达融合蛋白MBP-NS1,并获得了其多克隆抗体,抗体效价达到1∶32000。结论:在原核表达系统中表达、纯化了融合蛋白,制备抗NS1多克隆抗体,为进一步研究该病毒非结构蛋白基因的转录和翻译机制提供可靠的工具。     

抗鳞翅目害虫基因cry1C的抗原表位分析及多克隆抗体制备

利用生物信息学方法预测cry1C蛋白的抗原表位区,并命名为Δcry1C。优化Δcry1C的核苷酸序列并进行人工合成,构建重组表达载体pET28b(+)-Δcry1C。在E.coli中诱导表达His6-Δcry1C蛋白,纯化后免疫新西兰大白兔,分离、纯化获得cry1C多抗血清。ELISA测定结果表明,抗体效价最高可达1∶512 000。Western Blot分析结果表明,cry1C多克隆抗体能够与cry1C转基因抗虫水稻蛋白特异性结合。利用生物信息学筛选抗原表位区并优化序列、原核表达重组蛋白、免疫制备cry1C多克隆抗体,为深入研究抗鳞翅目害虫植物提供了前提条件。     

家蚕GAPDH内参蛋白多克隆抗体的制备及其检测

制备家蚕GAPDH内参蛋白多克隆抗体,并对该抗体进行检测。利用PCR技术从家蚕中克隆GAPDH基因,构建其原核表达载体,转化大肠杆菌,诱导表达重组蛋白并纯化。纯化后的蛋白作为抗原免疫新西兰大白兔制备GAPDH多克隆抗体。用酶联免疫吸附法和Western blot检测抗体的效价和特异性。结果显示,成功构建GAPDH/p ET-28a原核表达载体,获得高纯度的GAPDH重组融合蛋白;经SDS-PAGE和抗His单抗检测,纯化后蛋白的分子量大小与预测的一致;以该蛋白为免疫抗原,采用4次免疫方式对新西兰大白兔进行免疫,获得GAPDH多克隆抗体血清。酶联免疫吸附检测结果表明,GAPDH抗体的效价为1:8000,并能与天然家蚕蛋白特异性结合。成功制备了家蚕内参蛋白GAPDH多克隆抗体,为深入研究家蚕中不同蛋白的生理功能和作用奠定了坚实的基础。     

禽网状内皮组织增生病病毒gp90全长蛋白的原核表达、纯化及其免疫原性分析

摘要：【目的】原核表达免疫原性良好的禽网状内皮组织增生病病毒（( Reticuloendotheliosis virus, REV )gp90蛋白,并制备抗gp90蛋白高效价多克隆血清。【方法】利用PCR技术,以pMD18T-env为模板,扩增得到REV的gp90蛋白编码基因,将其克隆入表达载体pET-28a(+)中,将构建的原核表达质粒pET28-gp90,转化大肠杆菌（Escherichia coli ) BL21 (DE3) 感受态细胞,经异丙基硫代-β-D-半乳糖苷(IPTG)诱导后进行gp90蛋     

重组酶Exo、Beta和Gam在大肠杆菌中的表达与纯化

目的:构建exo、beta和gam基因的原核表达质粒,在大肠杆菌中表达、制备重组酶Exo、Beta和Gam。方法:将exo、beta和gam基因分别构建在原核表达载体pEGKG和pET28a上,分别转化大肠杆菌BL21(DE3)和DH5α,经IPTG诱导后,在大肠杆菌中获得可溶性表达蛋白,用柱层析方法纯化蛋白。结果:构建了原核表达质粒pET28a-exo、pET28a-beta、pET28a-gam和pEGKG-exo、pEGKG-beta、pEGKG-gam;SDS-PAGE结果表明重组酶融合蛋白His-Exo、GST-Exo、His-Beta、GST-Beta、His-Gam、GST-Gam得到可溶性表达;用His标签抗体和GST标签抗体通过Western印迹方法检测到纯化后的融合蛋白。结论:在大肠杆菌中诱导表达了λ噬菌体重组酶,并纯化获得了一定量的纯度较好的蛋白,为下一步制备检测用多克隆抗体奠定了基础。     

人HMGB1分子的克隆、重组蛋白表达与生物学活性

采用RT-PCR,从重症肝炎病人外周血单个核细胞（peripheral blood mononuclear cells PBMCs）的mRNA中扩增高迁移率族蛋白1（high mobility group box－1 protein,HMGB1）基因,构建重组表达质粒pGEX4T-1-HMGB1,转化入大肠杆菌,测序证实其序列与基因数据库中HMGB1基因(NM_002128)一致。诱导表达的融合蛋白GST-HMGB1,用Glutathione Sepharose 4B亲和层析纯化,经Thrombin酶切得到HMGB1。结果显示：经Western-blotting检测,GST-HMGB1 和HMGB1均具有免疫活性; ELISA和MTT检测发现,两者均能刺激RAW264.7细胞产生大量TNF-α,明显刺激HeLa细胞增殖。GST-HMGB1具有良好的生物学活性,为今后的研究打下了基础。     

VEGF receptor binding peptide‐linked high mobility box group‐1 box A as a targeting gene carrier for hypoxic endothelial cells

High mobility group box‐1 (HMGB‐1) is a nuclear protein that can bind to and condense plasmid DNA. In this study, we developed a recombinant VEGF receptor binding peptide (VRBP) linked to HMGB‐1 box A (VRBP‐HMGB1A) as a targeting gene carrier to hypoxic endothelial cells. Hypoxic endothelial cells in ischemic tissues of solid tumors are important targets for gene therapy. A recombinant VRBP‐HMGB1A expression vector, pET21a‐VRBP‐HMGB1A was constructed. VRBP‐HMGB1A was over‐expressed in BL21 strain and purified by nickel‐chelate affinity chromatography. Complex formation between VRBP‐HMGB1A and pCMV‐Luc was confirmed by gel retardation assay. pCMV‐Luc was retarded completely at a 2/1 weight ratio (peptide/plasmid). For transfection assays, calf pulmonary artery endothelial (CPAE) cells were incubated under hypoxia for 24 h, prior to transfection to induce the VEGF receptors on the cells. VRBP‐HMGB1A/pCMV‐Luc complexes were transfected to hypoxic CPAE cells. The highest transfection efficiency was at a 30/1 weight ratio (peptide/plasmid). In addition, VRBP‐HMGB1A had higher efficiency than poly‐L ‐lysine (PLL) specifically in hypoxic CPAE cells, However, VRBP‐HMGB1A had lower efficiency than PLL in 293, H9C2, and normoxic CPAE cells. In MTT assay, VRBP‐HMGB1A was less toxic than PLL to cells. In conclusion, VRBP‐HMGB1A is a potential gene carrier for targeting hypoxic endothelial cells and thus, may be useful for cancer gene therapy. J. Cell. Biochem. 110: 1094–1100, 2010. Published 2010 Wiley‐Liss, Inc.     

人HMGB1酸性尾端对其抗菌活性的影响

为研究人高迁移率族蛋白B1(high-mobility group box-1HMGB1)酸性尾端对其抗菌活 性的影响,提取人外周血单个核细胞总RNA,经RT\|PCR扩增得到编码人HMGB1的cDNA及其缺失酸性尾端的突变体cDNA(mcDNA),原核表达载体pQE\|80L分别表达重组人HMGB1蛋白(rhHMGB1)及缺失酸性尾端的突变体蛋白(mrhHMGB1),经Ni^2+_- NTA亲和层析柱纯化两种蛋白.通过试管稀释法、琼脂扩散法两种体外抗菌实验观察,并比较rhHMGB1mrhHMGB1抗菌活性的差异.实验结果显示,rhHMGB1对大肠杆菌JM109、ATCC2592 2、DH5α有明确的抗菌活性,其抗菌活性强弱依次为JM109>ATCC25922>DH5α,而mrhHMGB1 对大肠杆菌JM109、ATCC25922、DH5α则均无抗菌活性.实验结果表明,人HMGB1的酸性尾端对其抗菌活性的发挥至关重要,此研究为进一步探讨人HMGB1抗菌功能的机制奠定了基础.     

JH-4 reduces HMGB1-mediated septic responses and improves survival rate in septic mice

Inhibition of high mobility group box 1 (HMGB1) and restoration of endothelial integrity are emerging as attractive therapeutic strategies for the management of severe vascular inflammatory diseases. Recently, we found that JH-4, a synthesized decursin derivative, exhibited a strong anti-Hutchinson-Gilford progeria syndrome by efficiently blocking progerin-lamin A/C binding. In this study, we examined the effects of JH-4 on HMGB1-mediated septic responses and the survival rate in a mouse sepsis model. The anti-inflammatory activities of JH-4 were monitored based on its effects on lipopolysaccharide- or cecal ligation and puncture (CLP)-mediated release of HMGB1. The antiseptic activities of JH-4 were determined by measuring permeability, leukocyte adhesion, migration, and the activation of proinflammatory proteins in HMGB1-activated human umbilical vein endothelial cells and mice. JH-4 inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses in human endothelial cells. JH-4 also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in mice. In addition, treatment with JH-4 reduced CLP-induced release of HMGB1, sepsis-related mortality, and pulmonary injury in vivo. Our results indicate that JH-4 is a possible therapeutic agent to treat various severe vascular inflammatory diseases via the inhibition of the HMGB1 signaling pathway.     

Expression, purification and characterization of TAT-high mobility group box-1A peptide as a carrier of nucleic acids

High mobility group box 1 (HMGB1) is an abundant nuclear protein that binds to double-stranded DNA. HMGB1 is composed of high mobility (HMG) box A, box B, and C-terminal acidic regions. In this study, a recombinant TAT linked HMGB1 box A (rTAT-HMGB1A) peptide was expressed, purified, and characterized as a carrier of nucleic acids. The HMGB1A cDNA was amplified by PCR, and cloned into the pET21a expression vector with the TAT domain located at the N-terminus. The rTAT-HMGB1A peptide was overexpressed and purified using Nickel affinity chromatography. A recombinant HMGB1A (rHMGB1A) peptide without the TAT domain was also overexpressed and purified as a control. In gel retardation assays, both the rHMGB1A and rTAT-HMGB1A peptides formed complexes with DNA equally well. However, transfection assays showed that the rTAT-HMGB1A peptide had a higher gene transfer efficiency than rHMGB1A. Finally, rTAT-HMGB1A had no cytotoxicity to HEK 293 cells suggesting that rTAT-HMGB1A may be useful as a non-toxic gene delivery carrier.